<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03416543</url>
  </required_header>
  <id_info>
    <org_study_id>RIPH3-RNI17/BIC RA</org_study_id>
    <secondary_id>2017-A02678-45</secondary_id>
    <secondary_id>17 11 16</secondary_id>
    <nct_id>NCT03416543</nct_id>
  </id_info>
  <brief_title>Effect of a New BI-specifiC Antibody Towards Dendritic Cells on Inflammation in Rheumatoid Arthritis</brief_title>
  <acronym>BIC_RA</acronym>
  <official_title>Effect of a New BI-specifiC Antibody Towards Dendritic Cells on Inflammation in Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First, this study will evaluate, in vitro, the cellular composition of the synovial fluid
      from patient with rheumatoid arthritis or gout.

      Then samples will be test with a new format of bispecific antibody targeting dendritic cells.
      The production of IL-10 will be the principal criteria of judgment. Production of IL-6 and
      IFN will be checked as well.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rheumatoid arthritis (RA) is one of the most common autoimmune disease in adult. It exists
      several drugs but none target dendritic cells even if it seems they play a major role in the
      physiopathology.

      One of the unit of research of Tours recently develop a new format of bispecific antibody
      which target dendritic cells. The first results in PBMC (unpublished yet) show an increase of
      the production of IL-10 In this study, we are going to first evaluate the cellular
      composition of synovial fluid from patients with RA and patients with gout (for the
      comparison, because the inflammatory mechanisms are different) Then, we will use this new
      antibody and evaluate the response by dosing Il-10, IL-6 and IFN.

      The aim is to verify in vitro if, with this new drug, it is possible to reverse the
      inflammation and induce a tolerance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2018</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Production of IL-10</measure>
    <time_frame>48 hours</time_frame>
    <description>Evaluate the production of IL-10 by cells from synovial fluid after the use of a new antibody format</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Production of Il-6</measure>
    <time_frame>48 hours</time_frame>
    <description>Evaluate the production of IL-6 by cells from synovial fluid after the use of a new antibody format</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Production of IFN</measure>
    <time_frame>48 hours</time_frame>
    <description>Evaluate the production of IFN by cells from synovial fluid after the use of a new antibody format</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Gout</condition>
  <condition>Arthritis</condition>
  <arm_group>
    <arm_group_label>Puncture</arm_group_label>
    <description>Patient with RA or gout and performing a puncture. The aim is evaluate the cellular composition of synovial fluid then evaluate the response to a new BI-specifiC Antibody Towards Dendritic Cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Puncture</intervention_name>
    <description>Puncture necessary for daily practice in patients with acute arthritis of RA or Gout.</description>
    <arm_group_label>Puncture</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      synovial fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute arthritis of RA or Gout. Puncture necessary for daily practice
        (diagnostic or therapeutic)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female over 18 years old

          -  Proven and possible RA or Gout

          -  Arthritis accessible to a puncture

          -  Necessary puncture for diagnosis or therapeutic

        Exclusion Criteria:

          -  Microcrystalline rheumatism other than Gout

          -  Known SpA

          -  Septic arthritis

          -  Biomedicament treatment

          -  Patient having objected to the processing of his data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis MULLEMAN, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denis MULLEMAN, MD-PhD</last_name>
    <phone>02.47.47.59.17</phone>
    <phone_ext>+33</phone_ext>
    <email>denis.mulleman@univ-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guillaume LE MELEDO</last_name>
    <phone>02.47.47.59.17</phone>
    <phone_ext>+33</phone_ext>
    <email>guillaume.lemeledo@etu.univ-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rheumatology department, University Hospital, Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis MULLEMAN, MD-PhD</last_name>
      <phone>02.47.47.59.17</phone>
      <phone_ext>+33</phone_ext>
      <email>denis.mulleman@univ-tours.fr</email>
    </contact>
    <contact_backup>
      <last_name>Guillaume LE MELEDO</last_name>
      <phone>02.47.47.59.17</phone>
      <phone_ext>+33</phone_ext>
      <email>guillaume.lemeledo@etu.univ-tours.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Denis MULLEMAN, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2018</study_first_submitted>
  <study_first_submitted_qc>January 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2018</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Dendritics cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

